Edgar Filing: Primiano Christopher Brett - Form 4

Primiano Christop Form 4	pher Brett											
October 04, 2017												
FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									PPROVAL 3235-0287		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. <i>See</i> Instruction 1(b).	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								burden hou response	Estimated average burden hours per response 0.5		
(Print or Type Respon	nses)											
Primiano Christopher Brett Sym Kar				2. Issuer Name and Ticker or Trading Symbol Karyopharm Therapeutics Inc. [KPTI]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
				-	nsaction			Director 10% Owner X Officer (give title Other (specify below) below) below) SVP, OPS, BUS DEV, GC & SEC				
(Street) 4. If Amen Filed(Mont				dment, Date n/Day/Year)	e Original			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
NEWTON, MA	02459							Person	More than One Re	eporting		
(City) ((Zatate)	ip)	Table	I - Non-De	rivative S	ecurit	ies Acc	quired, Disposed o	f, or Beneficial	lly Owned		
			Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3,	(A) o of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common 10/ Stock	/02/2017			S <u>(1)</u>	1,500	D	\$ 12	11,381	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transacti Code (Instr. 8)	Securities Acquired (A) or Disposed of (D)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
			Code V	(Instr. 3, 4, and 5) (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: Primiano Christopher Brett - Form 4

Reporting Owners

Reporting Owner Name / Address		Relationships						
		Director	10% Owner	Officer	Other			
Primiano Christopher Brett C/O KARYOPHARM THERAPE 85 WELLS AVENUE NEWTON, MA 02459	EUTICS INC.			SVP, OPS, BUS DEV, GC & SEC				
Signatures								
/s/ Christopher B. Primiano	10/04/2017							
**Signature of Reporting	Date							

**Signature of Reporting Person

on

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.